Drug companies succeed in keeping payments to doctors secret
BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7426.1248-a (Published 27 November 2003) Cite this as: BMJ 2003;327:1248- Bob Burton
- Canberra
Lobbying by Australia's drug industry association, Medicines Australia, has persuaded the Australian Competition and Consumer Commission (ACCC) to scrap a proposal to require public disclosure of drug companies' sponsorship of doctors' travel and accommodation and other promotional benefits.
The commission, a government agency established to protect consumers from anticompetitive activity, had originally proposed accrediting a self regulatory code on the marketing of drugs developed by Medicines Australia member companies, subject to certain amendments.
The first amendment laid down that Medicines Australia publish details of all breaches of the code on its website in full and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.